Novo Nordisk, global healthcare company, has acquired all of the shares of a University of Bristol spin-out company — Ziylo — giving it full rights to a glucose blinding molecule platform to develop glucose responsive insulins.
More From BioPortfolio on "Novo Nordisk to acquire all shares of Bristol University spin-out company"